CW Advisors LLC Acquires 17,466 Shares of Cencora, Inc. $COR

CW Advisors LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 181.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 27,116 shares of the company’s stock after acquiring an additional 17,466 shares during the period. CW Advisors LLC’s holdings in Cencora were worth $8,131,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Atlantic Edge Private Wealth Management LLC grew its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Costello Asset Management INC bought a new position in shares of Cencora during the first quarter worth $28,000. Vermillion & White Wealth Management Group LLC grew its stake in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares in the last quarter. Twin Peaks Wealth Advisors LLC bought a new stake in Cencora in the 2nd quarter valued at $52,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Cencora in the 2nd quarter worth $61,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer owned 65,746 shares in the company, valued at $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,640 shares of company stock valued at $14,099,338 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

NYSE:COR opened at $337.43 on Friday. The firm has a market capitalization of $65.42 billion, a price-to-earnings ratio of 42.44, a PEG ratio of 1.59 and a beta of 0.63. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The business has a 50 day simple moving average of $339.40 and a 200-day simple moving average of $309.16. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the previous year, the company posted $3.34 EPS. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on COR. Robert W. Baird raised their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company boosted their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings cut Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. JPMorgan Chase & Co. lifted their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, Mizuho upped their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.